Corcept Therapeutics Incorporated filed a Form 8-K on September 23, 2026, disclosing the resignation of Sean Maduck as President of Corcept Endocrinology, effective October 1, 2026, and the terms of a subsequent consulting agreement between the company and Mr. Maduck.

Key Highlights

  • Resignation date: Sean Maduck notified the Board of Directors of his decision to resign on September 22, 2026, with the resignation effective October 1, 2026.
  • No disagreement stated: According to the filing, Mr. Maduck "did not resign because of any disagreement with the Company on any matter relating to the Company's operations, financial statements, policies or practices."
  • Consulting fee: Under the Consulting Services Agreement, Mr. Maduck will be paid a cash fee of $57,000 per month.
  • Consulting term: The agreement has an initial term expiring on September 30, 2027, unless earlier terminated, with either party able to terminate upon 30 days' prior written notice.
  • Stock options: During the consulting term, Mr. Maduck's previously awarded and currently outstanding stock options will continue to vest according to the original vesting schedule of each such stock option.
  • Successor named: The company disclosed that Justin Gunn will succeed Mr. Maduck, as announced in a press release dated September 23, 2026.

Maduck Departure and Consulting Arrangement at Corcept Therapeutics

According to the Form 8-K filed by Corcept Therapeutics Incorporated (NASDAQ:CORT), Sean Maduck, who served as President of Corcept Endocrinology, informed the company's Board of Directors on September 22, 2026 of his intention to resign. His resignation becomes effective October 1, 2026. The filing states the company thanked Mr. Maduck "for his significant contributions to the Company and his dedication to helping patients."

Concurrent with his departure, the company and Mr. Maduck entered into a Consulting Services Agreement dated September 22, 2026 and effective October 1, 2026. Under the agreement, Mr. Maduck will provide consulting services to the company's Chief Executive Officer and executive management team. The company disclosed that Mr. Maduck will receive a monthly cash fee of $57,000 for those services. The agreement runs through September 30, 2027, unless terminated earlier, and either party may end it with 30 days' prior written notice.

The filing also notes that Mr. Maduck's previously awarded and currently outstanding stock options will continue to vest on their original schedules during the consulting period. The company indicated the full text of the Consulting Services Agreement will be filed either as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending September 30, 2026, or by amendment to this Current Report. Separately, under Item 7.01, the company disclosed a press release issued September 23, 2026, announcing the retirement of Mr. Maduck and naming Justin Gunn as his successor.

What Was Disclosed

Corcept Therapeutics disclosed the resignation of its President of Corcept Endocrinology, Sean Maduck, effective October 1, 2026, along with a consulting agreement paying $57,000 per month through September 30, 2027, and the naming of Justin Gunn as successor.